Bio

Chen Yan is a partner at JunHe and her practice focuses on capital markets, PE/VC investment, fund formation, debt, restructuring and IPOs. She advises public and private companies on a wide range of matters, including mergers and acquisitions, outbound investment, foreign direct investment, corporate governance and compliance. Ms. Chen has clients in various industrial sectors including finance, manufacturing, retail, education, pharmacy, biology, solar energy, telecommunications, media, entertainment and infrastructure. Ms. Chen has extensive experience in private equity and venture capital investment. Her PE/VC clients include Goldman Sachs, Warburg Pincus, Temasek, Sequoia, Advent, MBK, CDH, CITIC Capital, China Everbright Healthcare, FountainVest, Qiming Venture, Highlight Capital, Prax, CIC, CoBuilder, Yuansheng BioVenture, Stone VC and Biotrack Capital. Ms. Chen has recently completed over 200 private equity investment and exit projects. M Some of her recent representative transactions include Goldman Sach in its investment I n a medical imaging center and Sequoia Capital in its investment in JD Finance. Other transactions include CITIC Capital in its investment in Pharmaron, CCBI in its investment in CooTek, Sequoia Capital in its investment in BGI (300676) and China Everbright Healthcare in its investment in Betta Pharma (300588). She also represented CIC in its investment in Didi, Sequoia Capital in its investment in a chain of eye hospitals and a beverage manufacturing company. Ms. Chen also represented Highlight Capital in its investment in Quyi, and an orthopedic medical equipment manufacturing company, and CDH and co-investors in their investment in a NEEQ medical equipment company. She also currently represents a wide range of companies in PE/VC fund investments, including Face++, Youxin.com, Tuhu.com, Mia, ITjuzi, wajiu.com and Wingtek.